Table 1 Baseline characteristics of the included patients from the ENRADAS trial

Age, years

42.9 ± 10.3

40.7 ± 9.7

45.1 ± 10.4

Male patients, n (%)

82 (68.3)

43 (70.5)

39 (66.1)

Symptom duration, years

14.8 ± 12.2

12.8 ± 11.4

16.9 ± 12.7

HLA-B27 positive, n (%)

108 (90)

54 (88.5)

54 (91.5)

ASDAS-CRP

2.8 ± 0.7

2.7 ± 0.7

2.8 ± 0.7

BASDAI, points NRS (0–10)

4.2 ± 1.5

4.1 ± 1.5

4.2 ± 1.5

BASFI, points NRS (0–10)

3.3 ± 2.2

2.9 ± 2.1

3.7 ± 2.2

CRP, mg/L

10.3 ± 12.1

7.9 ± 7.4

12.6 ± 15.2

CRP > 5 mg/L, n (%)

68 (57.1)

33 (55)

35 (59.3)

BASMI, points (0–10)

2.6 ± 2.2

2.2 ± 2.1

3.0 ± 2.3

mSASSS, points

13.8 ± 17.2

11.1 ± 15.6

16.6 ± 18.4

Patients with syndesmophytes at baseline, n (%)

68 (56.7)

32 (52.5)

36 (61.0)

BMI, kg/m²

27.2 ± 5.3

27.3 ± 5.2

27.2 ± 5.4